Carol E. O'Hear, Ph.D.
Affiliations: | 2004 | University of Washington, Seattle, Seattle, WA |
Area:
Molecular Biology, Pharmacy, PharmacologyGoogle:
"Carol O'Hear"Parents
Sign in to add mentor| Jefferson Foote | grad student | 2004 | University of Washington | |
| (Antibody buffering: A novel mechanism of drug delivery.) | ||||
| Daniel S Chen | research scientist | 2014-2018 | Genentech, Inc. (Microtree) | |
| (Cancer Immunotherapy) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Hamid O, Molinero L, Bolen CR, et al. (2019) Safety, Clinical Activity, and Biological Correlates of Response in Patients With Metastatic Melanoma: Results From a Phase I trial of Atezolizumab. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Liu JF, Gordon M, Veneris J, et al. (2019) Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers. Gynecologic Oncology |
| Emens LA, Cruz C, Eder JP, et al. (2018) Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study. Jama Oncology |
| Horn L, Gettinger SN, Gordon MS, et al. (2018) Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. European Journal of Cancer (Oxford, England : 1990). 101: 201-209 |
| Kim JW, Shaffer DR, Massard C, et al. (2018) A phase Ia study of safety and clinical activity of atezolizumab (atezo) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 36: 187-187 |
| Kim D, Gadgeel SM, Gettinger SN, et al. (2018) Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK+ advanced NSCLC (aNSCLC). Journal of Clinical Oncology. 36: 9009-9009 |
| Molinero L, Chang C, Udyavar A, et al. (2018) Abstract P2-09-13: Molecular characterization of tumors from metastatic TNBC patients treated with atezolizumab (atezo) Cancer Research. 78 |
| Petrylak DP, Powles T, Bellmunt J, et al. (2017) Atezolizumab (atezo) in patients with metastatic urothelial carcinoma (mUC): A 2-year clinical update from a phase Ia study. Journal of Clinical Oncology. 35: 290-290 |
| Fleming GF, Emens LA, Eder JP, et al. (2017) Clinical activity, safety and biomarker results from a phase Ia study of atezolizumab (atezo) in advanced/recurrent endometrial cancer (rEC). Journal of Clinical Oncology. 35: 5585-5585 |
| Schmid P, Hegde PS, Zou W, et al. (2016) Association of PD-L2 expression in human tumors with atezolizumab activity. Journal of Clinical Oncology. 34: 11506-11506 |